Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma

doi:10.4240/wjgs.v17.i3.103740

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=0

Mar 27, 2025 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Surg. Mar 27, 2025; 17(3): 103740
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.103740

Open in New Tab Full Size Figure Download Figure

Figure 1 Hepatocellular carcinoma patients recommended for neoadjuvant therapy in the Chinese guideline for diagnosis and treatment of hepatocellular carcinoma (2024 edition). CNLC: China Liver Cancer Stage; PS: Performance status. Created by figdraw.com (Supplementary material).

Citation: Zhang XD, Zhang LY, Luo JL, Yu KH, Zhu KL. Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(3): 103740
URL: https://www.wjgnet.com/1948-9366/full/v17/i3/103740.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i3.103740